Important Information about Feraheme® (ferumoxytol) Injection

Coding for Feraheme

Coverage and Feraheme-specific codes

  • Over 90% commercial coverage without restrictions1
  • Feraheme-specific Q codes
  • Coverage across all Medicare Administrative Contractors1
Coding for Feraheme® (ferumoxytol) Injection

*This table is provided for informational purposes only. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and specific billing requirements. AMAG Pharmaceuticals®, Inc. does not make any representation or guarantees concerning reimbursement or coverage for any service or item.

Payers may require the N18-series code for anemia in chronic renal disease and/or the IDA codes on the claim. Payers may require a primary and secondary diagnosis code related to CKD and IDA. Sequencing of codes may vary based on patient’s condition and payer’s policy. Check with your payer.

Medicare pricing changes quarterly. Allowed amounts can be found at http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2015ASPFiles.html.

§This code is trademarked to the American Medical Association. All rights reserved.

CKD: chronic kidney disease; CPT: Current Procedural Terminology; ESRD: end-stage renal disease; HCPCS: Healthcare Common Procedure Coding System; IDA: iron deficiency anemia
 
Important Information about Feraheme® (ferumoxytol) Injection

Indication and Dosing

Feraheme is indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD).

The recommended dose of Feraheme is an initial 510 mg dose followed by a second 510 mg dose 3 to 8 days later, each dose infused over at least 15 minutes while the patient is in a reclined or semi-reclined position.

Important Safety Information

WARNING: RISK FOR SERIOUS HYPERSENSITIVITY/ANAPHYLAXIS REACTIONS

Fatal and serious hypersensitivity reactions including anaphylaxis have occurred in patients receiving Feraheme.  Initial symptoms may include hypotension, syncope, unresponsiveness, cardiac/cardiorespiratory arrest.

  • Only administer Feraheme when personnel and therapies are immediately available for the treatment of anaphylaxis and other hypersensitivity reactions.
  • Observe for signs or symptoms of hypersensitivity reactions during and for at least 30 minutes following Feraheme infusion including monitoring of blood pressure and pulse during and after Feraheme administration.
  • Hypersensitivity reactions have occurred in patients in whom a previous Feraheme dose was tolerated.

Contraindications

Feraheme is contraindicated in patients with:

  • Known hypersensitivity to Feraheme or any of its components
  • History of allergic reaction to any intravenous iron product

Warnings and Precautions

  • Fatal and serious hypersensitivity reactions including anaphylaxis, presenting with cardiac/cardiorespiratory arrest, clinically significant hypotension, syncope, or unresponsiveness have occurred in patients receiving Feraheme.  Other adverse reactions potentially associated with hypersensitivity have occurred (pruritus, rash, urticaria, and wheezing).  These reactions have occurred following the first dose or subsequent doses in patients in whom a previous Feraheme dose was tolerated.
  • Patients with a history of multiple drug allergies may have a greater risk of anaphylaxis with parenteral iron products.  Carefully consider the potential risks and benefits before administering Feraheme to these patients.
  • Only administer Feraheme when personnel and therapies are immediately available for the treatment of anaphylaxis and other hypersensitivity reactions.  Closely observe patients for signs and symptoms of hypersensitivity including monitoring of blood pressure and pulse during and after Feraheme administration for at least 30 minutes and until clinically stable following completion of each infusion.
  • In clinical studies predominantly in patients with CKD, serious hypersensitivity reactions were reported in 0.2% (3/1,726) of subjects receiving Feraheme.  Other adverse reactions potentially associated with hypersensitivity (e.g., pruritus, rash, urticaria or wheezing) were reported in 3.7% (63/1,726) of these subjects.  In other trials excluding patients with Stages 4 and 5 CKD, moderate to severe hypersensitivity reactions were reported in 2.6% (26/1,014) of patients treated with Feraheme.
  • Elderly patients with multiple or serious co-morbidities who experience hypersensitivity reactions and/or hypotension following administration of Feraheme may have more severe outcomes.
  • In the post-marketing experience, fatal and serious anaphylactic type reactions presenting with cardiac/ cardiorespiratory arrest, clinically significant hypotension, syncope, and unresponsiveness have been reported.  Elderly patients with multiple or serious co-morbidities who experience hypersensitivity reactions and/or hypotension following administration of Feraheme may have more severe outcomes.
  • Severe adverse reactions of clinically significant hypotension have been reported in the post-marketing experience. In clinical studies, hypotension was reported in 1.9% (33/1,726) of subjects, including three patients with serious hypotensive reactions. Monitor for signs and symptoms of hypotension following each Feraheme administration.
  • Excessive therapy with parenteral iron can lead to excess storage of iron with the possibility of iatrogenic hemosiderosis. Patients should be regularly monitored for hematologic response during parenteral iron therapy, noting that lab assays may overestimate serum iron and transferrin bound iron values in the 24 hours following administration of Feraheme.
  • As a superparamagnetic iron oxide, Feraheme may transiently affect magnetic resonance diagnostic imaging studies for up to 3 months following the last Feraheme dose. Feraheme will not affect X-ray, CT, PET, SPECT, ultrasound, or nuclear imaging.

Adverse Reactions

  • The most common adverse reactions (≥ 2%) following the administration of Feraheme are diarrhea, nausea, dizziness, hypotension, constipation, and peripheral edema.
  • In clinical trials, adverse reactions leading to treatment discontinuation and occurring in ≥ 2 Feraheme-treated patients included hypotension, infusion site swelling, increased serum ferritin level, chest pain, diarrhea, dizziness, ecchymosis, pruritus, chronic renal failure, and urticaria.
  • The following additional serious adverse reactions have been reported from the post-marketing experience with Feraheme:  tachycardia/rhythm abnormalities, angioedema, ischemic myocardial events, congestive heart failure, pulse absent, and cyanosis. These adverse reactions have usually occurred within 30 minutes after the administration of Feraheme. Reactions have occurred following the first dose or subsequent doses of Feraheme.
Reference: 1. Data on file, AMAG Pharmaceuticals, Inc. as of May 2014.